BJMO - volume 10, issue 7, november 2016
T. Vermassen PhD, A. De Meulenaere MD, M. Van de Walle MD, S. Rottey MD, PhD
Renal cell carcinoma accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for renal cell carcinoma patients has changed tremendously. In this review, we will summarise the treatment options currently available for clear-cell localised, advanced and metastatic renal cell carcinoma; as stated in the ESMO clinical practice guidelines, the EAU guidelines and the NCCN guidelines. Furthermore we will discuss the recommended therapies in patients diagnosed with non-clear cell tumours.
(BELG J MED ONCOL 2016;10(7):256–262)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.